Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients.

European journal of clinical pharmacology - 1 Jul 2001

Lohmann P L, Rao M L, Ludwig M, Griese E U, Zanger U M, Mörike K, Maier W, Bagli M

Abstract excerpt

OBJECTIVE: To investigate the influence of CYP2D6 genotype and medication on the reliability of phenotyping in a naturalistic setting of psychiatric inpatients. METHODS: The phenotype of 160 psychiatric inpatients was estimated by taking the urinary metabolic ratio (MR) of the concentrations of sparteine to 2- and 5-dehydrosparteine. Genotyping identified CYP2D6*1, *3, *4, *5 and *6 alleles as well as duplication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Phenotype

Share to Selective Serotonin Reuptake Inhibitors

Share to Sparteine

Source

Identifiers

PMID: 11549206
DOI: 10.1007/s002280100299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients.PMID 11549206Read ↗

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.Semantic proximity Read ↗

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implicationSemantic proximity Read ↗

Pharmacogenetics of antidepressants: clinical aspects.Semantic proximity Read ↗

Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants.Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.Semantic proximity Read ↗

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.Semantic proximity Read ↗

Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.Semantic proximity Read ↗

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.Semantic proximity Read ↗

Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype.Semantic proximity Read ↗

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.